Lataa...
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome
IMPORTANCE: In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of s...
Tallennettuna:
| Julkaisussa: | JAMA Neurol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885255/ https://ncbi.nlm.nih.gov/pubmed/29482205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.5144 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|